POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions, essential for maintenance of intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Dextrose 5% provides caloric support and may help prevent ketosis. Sodium chloride 0.33% provides sodium and chloride ions to maintain electrolyte balance and osmotic pressure.
| Metabolism | Potassium is not metabolized; it is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle. Sodium and chloride are primarily excreted renally. |
| Excretion | Potassium is primarily excreted renally (90%) with minor fecal (10%) losses. Renal elimination involves glomerular filtration and distal tubular secretion; 80-90% is reabsorbed, with excretion adjusted by aldosterone. In dextrose/saline, potassium excretion parallels sodium and water handling. |
| Half-life | The terminal half-life is approximately 2-4 hours in patients with normal renal function. Clinical context: half-life extends significantly in renal impairment (e.g., up to 24-48 hours in oliguric patients) and is dependent on total body potassium stores and redistribution kinetics. |
| Protein binding | Potassium is not significantly bound to plasma proteins; binding is <5% (negligible). |
| Volume of Distribution | The apparent volume of distribution is approximately 0.5-0.8 L/kg, reflecting distribution primarily into the extracellular fluid (ECF) (15% total body water) and gradual uptake into intracellular fluid (ICF) via Na+/K+-ATPase. |
| Bioavailability | Intravenous: 100% bioavailability. Oral (not in this formulation): typically 90-95%. For this product, only IV administration is relevant. |
| Onset of Action | Intravenous infusion: onset within seconds to minutes as potassium is directly infused into circulation. Oral (not applicable here, but IV context): immediate effect on serum potassium but full intracellular repletion requires hours to days. |
| Duration of Action | Intravenous: duration of effect correlates with infusion rate and redistribution; serum levels decline rapidly (within 30-60 minutes) after infusion stops, but intracellular repletion lasts longer (hours to days). Continuous IV infusion provides sustained effect. |
Intravenous infusion at a rate determined by serum potassium levels; typical maintenance: 10-20 mEq potassium per hour, not to exceed 40 mEq/hour; maximum daily dose: 200 mEq. Adjust based on patient's electrolyte status and renal function.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in anuria; for GFR 30-60 mL/min: reduce infusion rate by 25%; for GFR 15-30 mL/min: reduce infusion rate by 50%; for GFR <15 mL/min: avoid use unless severe hypokalemia and close monitoring. |
| Liver impairment | No specific dose adjustment per Child-Pugh score; monitor serum potassium and renal function as hepatic impairment may affect electrolyte balance. |
| Pediatric use | Dose based on body weight: 0.2-0.5 mEq/kg/hour for 1-2 hours, then reassess; maximum infusion rate: 0.5 mEq/kg/hour; maximum daily dose: 3 mEq/kg. Use with caution and monitor serum potassium frequently. |
| Geriatric use | Start at low end of dosing range (e.g., 10 mEq/hour) due to age-related decline in renal function; monitor serum potassium and renal function closely; avoid rapid infusion. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium, dextrose, and sodium chloride are normal milk components. No M/P ratio available. Compatible with breastfeeding at therapeutic doses. Monitor infant for electrolyte imbalance if mother receives high doses. |
| Teratogenic Risk | First trimester: No evidence of teratogenicity from potassium, dextrose, or sodium chloride at standard doses. Second and third trimesters: No specific fetal risks reported. High doses may cause electrolyte disturbances affecting fetal homeostasis. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions are for intravenous infusion after dilution only. Direct injection or undiluted infusion may cause cardiac arrest and sudden death. Must be used with extreme caution, especially in patients with renal impairment, cardiac disease, or hyperkalemia.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia (serum potassium >5.5 mEq/L)","Severe renal impairment with oliguria or anuria","Concomitant use with potassium-sparing diuretics, ACE inhibitors, or ARBs unless closely monitored","Acute dehydration","Adrenal insufficiency","Hypersensitivity to any component"]
| Precautions | ["Risk of hyperkalemia, especially in patients with renal impairment, diabetes, or other conditions predisposing to potassium retention","Monitor serum potassium, glucose, and electrolyte levels regularly","Do not administer if solution is cloudy or contains precipitate","Use with caution in patients with heart failure, severe renal impairment, or conditions causing edema","Extravasation risk: avoid infiltration into perivascular tissue"] |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes (potassium, sodium, glucose), renal function, urine output, and fluid balance. In pregnancy, monitor for signs of hyperkalemia or hyperglycemia. Fetal heart rate monitoring as clinically indicated. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. Electrolyte disturbances secondary to high doses may theoretically impact reproductive function, but no specific data. |